

IN THE UNITED STATES PATEN	I AND I RADEMARK OFFICE
In re the Application of:  Applicant: Chanda B. Zaveri  Serial No.: 10/632,389  Filed: July 31, 2003  For: PEPTIDES WITH WOUND HEALING ACTIVITY	Group Art Unit: To Be Assigned  Examiner: To Be Assigned
TRANSMITTA	AL LETTER
Commissioner for Patents Washington, D.C. 20231 Sir:	
<ul> <li>Enclosed are the following documents:</li> <li>Information Disclosure Statement;</li> <li>Form PTO/SB/08A; and</li> <li>Return Postcard.</li> </ul>	
CERTIFICATE (37 C.F.R)  I hereby certify that this paper (along with anything referred to as being attacent the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with sufficient postage as First Class Mail in an environment of the date shown below with the date shown below wit	. §1.8a) ched or enclosed) is being deposited with the United States Postal Service relope addressed to the Commissioner for Patents, Washington, D.C.
10/7/03	Name of Person Mailing Paper  Megan Massey Name of Person Mailing Paper  Signature of Person Mailing Paper

SDILIB1\MAM2\465915.01

No fee is believed due with this submission; however, the Commissioner is authorized to charge any fee required, or to credit any overpayment, to our Deposit Account No. 50-2613.

Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Michael B. Farber, Ph.D., Esq.

Reg. No. 32,612

MBF:mam

PAUL, HASTINGS, JANOFSKY & WALKER LLP

3579 Valley Centre Drive San Diego, CA 92130-2081 Phone: (858) 720-2500

Fax: (858) 720-2555



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	) Group Art Unit: To Be Assigned
Applicant: Chanda B. Zaveri	)  Examiner: To Be Assigned
Serial No.: 09/632,389	) )
Filed: July 31, 2003	) )
For: PEPTIDES WITH WOUND HEALING ACTIVITY	) ) )
INFORMATION DISCLOSURE STAT	EMENT UNDER 37 CFR § 1.97(b)(3)
Assistant Commissioner for Patents Washington, D.C. 20231	
Sir:	
In compliance with the Applicant's duty und	ler 37 CFR § 1.56, the following information is
brought to the attention of the Examiner. The item	s are listed on the attached form PTO-1449 and
copies are enclosed for the convenience of the Exam	miner.
The items identified in this Information Dis	closure Statement (IDS) may or may not be
"material" pursuant to 37 CFR § 1.56 and the subm	nission thereof by Applicant shall not be construed
as an admission that any such patent, publication of	r other information referred to therein is material
CERTIFICATE (37 C.F.I	
I hereby certify that this paper (along with anything referred to as being atta on the date shown below with sufficient postage as First Class Mail in an en 20231.	ached or enclosed) is being deposited with the United States Postal Service
Date of Deposit	Megan Massey Name of Person Mailing Paper  Signature of Person Mailing Paper

SDILIBI\MAM2\465919.01

Patent 37896.00002.DIV2

or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

The filing of this IDS shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.

The attached IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of a first Office Action on the merits. Thus, no petition or fee is required. However, if the undersigned representative of Applicant is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c) and is further authorized to charge any fee required by the filing of these papers to Paul, Hastings, Janofsky & Walker's Deposit Account No. 50-2613.

Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Dated:

By:

Michael B. Farber, Ph.D., Esq.

Reg. No. 32,612

MBF:mam

PAUL, HASTINGS, JANOFSKY & WALKER LLP

3579 Valley Centre Drive San Diego, CA 92130

San Diego, CA 92130 Phone: (858) 720-2500

Fax: (858) 720-2555

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	

Complete if Kn wn					
Application Number	10/632,389				
Filing Date	July 31, 2003				
First Named Inventor	Chanda B. Zaveri				
Group Art Unit	TBA				
Examiner Name	TBA				
Attorney Docket Number	37896.00002DIV2				

				U.S. PATENT DOCU		Pages, Columns, Lines,
Examine r Initials*			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
	AA	4,148,788	<u> </u>	Wang	04-10-1979	
	AB	4,353,821		Birr, et al.	10-12-1982	
	AC	4,466,918		Birr, et al.	08-21-1984	
	AD	4,470,926		Birr, et al.	09-11-1984	
	AE	4,612,365		Birr, et al.	09-16-1986	
	AF	4,614,731		Horecker	09-30-1986	
	AG	4,659,694		Horecker	04-21-1987	
	AH	4,696,915		Horecker	09-29-1987	
	Al	4,716,148		Horecker	12-29-1987	
	AJ	4,816,566		DeChiara, et al.	03-28-1989	
	AK	4,855,407		Wang	08-08-1989	
	AL	4,910,296		Birr, et al.	03-20-1990	
	AM	5,459,237		Berkowitz, et al.	10-17-1995	**************************************
	AN	5,470,950		Maloy, et al.	11-28-1995	<u> </u>
	AO	5,512,656		Wang	04-30-1996	
	AP	5,654,274		Kari	08-05-1997	
	AQ	5,721,211		Moody	02-24-1998	
	AR	6,063,986		Latche, et al.	05-16-2000	
	AS	6,204,360		Pang	03-20-2001	
	AT	6,235,716		Ben-Sasson	05-22-2001	
	AU	6,287,606		Bockman, et al.	09-11-2001	
	AV	6,319,907		Ferguson	11-20-2001	
	AW	6,331,409		Livant	12-18-2001	

			<u> </u>	FOREIGN PA	ATENT DOCUMEN	TS		
Examiner	Cite		Foreign Patent Docu		Name of Patentee or Applicant of Cited	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials	No.	Office <sup>3</sup>	Number <sup>4</sup>	known)	Document	MM-DD-YYYY	Passages or Relevant Figures Appear	T <sup>6</sup>

Examiner Signature	Date Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

ease type a plus sign (+) inside this box -> +

Substitute for form 1449A/PTO

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Index the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/632389

Filing Date July 31, 2003

First Named Inventor Chanda B. Zaveri

Group Art Unit TBA

Examiner Name TBA

	(use as m	any sheets as n	ecessary)	Examiner Name	TBA	
Sheet	2	of	2	Attorney Docket Number	37896.00002.DIV2	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AX	EMBL Data Library Accession No. T16855, "Hypothetical Protein T13A10-1-Caenorhabditis elegans," September 20, 1999 (original submission April 1996).	
	AY	HANNAPPEL, et al., "Isolation and Characterization of Thymosin β <sub>9</sub> <sup>Met</sup> from Pork Spleen," <u>Arch. Biochem. Biophys.</u> 273: 396-402 (1989).	
	AZ	HANNAPPEL, et al., "Thymosins $\beta_8$ and $\beta_9$ : Two New Peptides Isolated from Calf Thymus Homologous to Thymosin $\beta_4$ ," <u>Proc. Nat. Acad. Sci. USA</u> 79: 1708-1711 (1982).	
	ВА	MCCREARY, et al., "Sequence of a Human Kidney cDNA Clone Encoding Thymosin β <sub>10</sub> ," <u>Biochem. Biophys. Res. Commun.</u> 152: 862-866 (1988)	
	ВВ	SHARMA, et al., "Diversity of Circumsporozoite Antigen Genes from Two Strains of the Malarial Prarsite <i>Plasmodium knowlesi</i> ," <u>Science</u> 229:779-782 (1985)	

Date Considered	
	Date Considered

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.